Table 5 Patient characteristics
Diverted anorectal cancer (n = 10) | Non-diverted anorectal cancer (n = 31) | p | |
|---|---|---|---|
Sex, male/female | 5/5 | 8/23 | 0.229 |
Age at diagnosis with CD (years) | 18 (9–30) | 23 (11–47) | 0.098 |
Site of CD, colic/ileocolic | 2/8 | 4/27 | 0.585 |
Type of CD perforative, n (%) | 8 (80) | 25 (80.6) | 0.865 |
Smoking, n (%) | 3 (30) | 8 (38) | 0.797 |
Biologic administration, n (%) | 2 (20) | 17 (54.8) | 0.057 |
Immunomodulator administration, n (%) | 2 (20) | 12 (38.7) | 0.283 |
Surveillance biopsy for anorectal lesion, n (%) | 1 (10) | 3 (9.6) | 1 |
Tumor site, n (%) | 0.953 | ||
Anorectum | 7(70) | 22(71) | |
Perianal | 3(30) | 9(29) | |
Cancer diagnosis | 0.237 | ||
Preoperative biopsy | 7 | 27 | |
During operation | 2 | 2 | |
Resected specimen | 1 | 2 | |
Maximum tumor size (mm) | 65 (12–130) | 51 (8–85) | 0.148 |
T category | 0.185 | ||
0/1/2/3/4 | 0/1/0/4/5 | 1/4/4/12/10 | |
N category | 0.453 | ||
0/1/2 | 6/2/2 | 22/3/6 | |
Lymphatic vessel invasion ± | 5/5 | 9/22 | 0.226 |
Vascular invasion ± | 6/4 | 11/20 | 0.187 |
muc component ± | 8/2 | 18/13 | 0.256 |
por component ± | 4/6 | 9/22 | 0.093 |
Radial margin ± | 6/4 | 15/16 | 0.588 |
UICC TNM stage | 0.105 | ||
0/I/II/III/IV | 0/1/5/2/2 | 1/7/14/9/ 0 | |
Recurrence or remnant of cancer ± | 9/1 | 10/21 | 0.003* |
Observation time after APR (months) | 28 (12–151) | 47 (1–216) |